Sapanisertib is a dual mTORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. The Food and Drug Administration (FDA) has granted Fast Track designation to ...

SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, announced that updates ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted fast track designation to sapanisertib for treatment of certain patients with non-small cell ...

First-in-human phase 1 trial of the safety, tolerability, pharmacokinetics of BY101298: Initial report from dose escalation cohort. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, ...

The MarketWatch News Department was not involved in the creation of this content. Randomized phase 2 study in platinum-resistant ovarian cancer met its prespecified hazard ratio target and primary ...

(RTTNews) - The U.S. Food & Drug Administration has granted Fast Track designation for Calithera Biosciences Inc.'s (CALA) investigational mTORC 1/2 inhibitor sapanisertib (CB-228) for the treatment ...

AUSTIN, TX and PHILADELPHIA, PA—March 12, 2025—Faeth Therapeutics (Faeth), a clinical-stage biotechnology company focused on metabolism, and The GOG Foundation, Inc. (GOG-F), a not-for-profit ...

Plasmodium kinases represent promising antimalarial drug targets. Arendse et al. show that sapanisertib — an inhibitor of the human mammalian target of rapamycin complex being clinically investigated ...

Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation SOUTH SAN FRANCISCO, Calif., Oct.